Page 1 of 5

Dutasteride reduces risk of prostate carcinoma diagnosis in high-risk men

Dutasteride ( Avodart ) has shown to reduce the risk of a prostate cancer diagnosis by 23 percent in men with an increased risk of the disease. The results are reported in the New England Journal of Medicine ( NEJM ). The four-year study found that Dutasteride significantly reduced the chances t...
Read Article

Advanced non-small cell lung cancer: Vandetanib has shown clinical benefit when combined with Docetaxel

When combined with standard chemotherapy, Vandetanib ( Zactima ) improves progression-free survival for patients with advanced non-small cell lung cancer. The findings, presented at the American Society of Clinical Oncology's Annual Meeting, mark the first clinical benefit of a small molecule tar...
Read Article

Metastatic colon cancer: better surgical interventions, new chemotherapeutic and biological agents increase 5-year survival from 8 to 30 percent

Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease. Published in the Journal of Clinical Oncology, it is the first study in the last 20 y...
Read Article

Metastatic colorectal cancer: better surgical interventions, new chemotherapeutic and biological agents increase 5-year survival from 8 to 30 percent

Novel chemotherapy and biological agents for metastatic colorectal cancer, combined with surgical advances in liver resection, have resulted in a dramatic increase in survival for patients with advanced disease. Published in the Journal of Clinical Oncology, it is the first study in the last 20 y...
Read Article

Metastatic HER2+ breast cancer: a combination of Capecitabine, Vinorelbine, and Trastuzumab is promising option

Combining two chemotherapy drugs with Trastuzumab ( Herceptin ) to treat women who have metastatic HER2+ breast cancer may offer physicians another choice in their treatment options. At the 45th Annual Meeting of the American Society of Clinical Oncology ( ASCO ), researchers from the Mayo Clinic...
Read Article

Anti-angiogenesis inhibitors may improve outcomes of patients with sex cord-stromal tumors

Researchers at The University of Texas M. D. Anderson Cancer Center have found that increased angiogenesis and vascular endothelial growth factor expression are associated with poor survival in women with sex cord-stromal ovarian tumors. This data was presented at the Society of Gynecologic Oncol...
Read Article

Nexavar significantly extends overall survival in hepatocellular carcinoma patients

Sorafenib ( Nexavar ) tablets has significantly extended overall survival in patients with hepatocellular carcinoma ( HCC ), or primary liver cancer versus those taking placebo by 44% ( HR=0.69; p-value=0.0006 ). The Phase 3, placebo-controlled Sorafenib HCC Assessment Randomized Protocol ( SHARP...
Read Article

Lapatinib in brain metastases associated with breast cancer

One-third of women with HER2-positive metastatic breast cancer currently develop brain metastases. Once the disease advances to this stage, overall disease prognosis is poor with the average one-year survival from diagnosis estimated at about 20 percent. Results from an ongoing, multicenter Pha...
Read Article

Lapatinib in combination with Paclitaxel as first-line treatment for patients with metastatic or relapsed advanced breast cancer

Paclitaxel ( Taxol ) is one of the most commonly used chemotherapies in breast cancer. Therefore, the evaluation of Lapatinib ( Tykerb ) in combination with this treatment is of high importance. A large, randomized, multicenter, prospective trial evaluated a total of 580 patients either negative...
Read Article

Chest X-ray exposure may increase likelihood of breast cancer

An analysis of 1,600 women with BRCA 1/2 mutations suggests that exposure to chest X-rays may increase the risk of breast cancer, and that exposure before the age of 20 may be linked to particularly heightened risk. The research, conducted by a consortium of European cancer centers, was the firs...
Read Article